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Abstract
Objective: To investigate relationships between mortality and circulating
25-hydroxyvitamin D (25(OH)D), 25-hydroxycholecalciferol (25(OH)D3) and
25-hydroxyergocalciferol (25(OH)D2).
Design: Case–cohort study within the Melbourne Collaborative Cohort Study
(MCCS). We measured 25(OH)D2 and 25(OH)D3 in archived dried blood spots by
LC–MS/MS. Cox regression was used to estimate mortality hazard ratios (HR), with
adjustment for confounders.
Setting: General community.
Subjects: The MCCS included 29 206 participants, who at recruitment in 1990–1994
were aged 40–69 years, had dried blood spots collected and no history of cancer.
For the present study we selected participants who died by 31 December 2007
(n 2410) and a random sample (sub-cohort, n 2996).
Results: The HR per 25nmol/l increment in concentration of 25(OH)D and 25(OH)D3
were 0·86 (95% CI 0·78, 0·96; P=0·007) and 0·85 (95% CI 0·77, 0·95; P=0·003),
respectively. Of 5108 participants, sixty-three (1·2%) had detectable 25(OH)D2; their
mean 25(OH)D concentration was 11·9 (95% CI 7·3, 16·6) nmol/l higher (P<0·001).
The HR for detectable 25(OH)D2 was 1·80 (95% CI 1·09, 2·97; P=0·023); for those
with detectable 25(OH)D2, the HR per 25nmol/l increment in 25(OH)D was 1·06
(95% CI 0·87, 1·29; P interaction=0·02). HR were similar for participants who
reported being in good, very good or excellent health four years after recruitment.
Conclusions: Total 25(OH)D and 25(OH)D3 concentrations were inversely
associated with mortality. The ﬁnding that the inverse association for 25(OH)D
was restricted to those with no detectable 25(OH)D2 requires conﬁrmation in
populations with higher exposure to ergocalciferol.
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Many cohort studies have reported inverse associations
between circulating 25-hydroxyvitamin D (25(OH)D)
and mortality(1). Vitamin D exists in two forms,
ergocalciferol (vitamin D2) and cholecalciferol
(vitamin D3); 25-hydroxyergocalciferol (25(OH)D2) and
25-hydroxycholecalciferol (25(OH)D3) can be quantiﬁed
separately; and a large study of their relative prevalence in
New York has been published(2). However, no cohort
studies of mortality have presented associations separately
for 25(OH)D2 and 25(OH)D3; many used assays such as
RIA and chemiluminescent immunoassays(1) that cannot
quantify them separately.
Cholecalciferol is the natural form of vitamin D in
man, endogenously synthesised following UVB irradiation
of 7-dehydrocholesterol in skin(3). Dietary sources of
cholecalciferol include fatty ﬁsh, fortiﬁed foods and
supplements(3). Ergocalciferol, an exogenous form of
vitamin D, is produced in fungi following UVB irradiation
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of ergosterol. People can obtain ergocalciferol from some
fortiﬁed foods (e.g. margarine)(4) and some species of
mushrooms, and it is used in supplements in some
countries(3,5). In Australia, margarine contains low levels of
ergocalciferol (1 μg/100 g)(6).
A systematic review and meta-analysis of randomised
controlled trials (RCT) comparing the effects of ergocalci-
ferol and cholecalciferol supplementation on 25(OH)D
concentrations found that cholecalciferol is more effective
than ergocalciferol at increasing serum 25(OH)D(4),
especially when given as large weekly or monthly doses.
Ergocalciferol might also increase catabolism of
cholecalciferol; several RCT have reported that ergocalci-
ferol supplementation lowered 25(OH)D3 concentra-
tions(7–13). Reviews of RCT of the effects of vitamin D
supplementation on mortality show that there was a
modest decrease in mortality for trials of cholecalciferol
supplementation, but no decrease for trials of ergocalci-
ferol supplementation, although the ergocalciferol trials
were few and of relatively low quality(1,5).
Given limited evidence from trials that ergocalciferol
and cholecalciferol supplementation might have different
effects on mortality, observational studies of 25(OH)D and
mortality should separate the two forms. The advent of
liquid chromatography–tandem mass spectrometry
(LC–MS/MS) now makes this possible because it enables
simultaneous separate measurement of 25(OH)D2 and
25(OH)D3. We report here analyses of 25(OH)D,
25(OH)D3 and 25(OH)D2 in relation to all-cause mortality
in a prospective cohort study of middle-aged men and
women. The large size of the study and the availability of
data on self-reported health about four years after
recruitment also enabled us to assess the potential impact
of reverse causality, which has been a major limitation of
existing cohort studies.
Methods
Study design
A case–cohort study to investigate vitamin D status and
risk of cancer, diabetes and mortality was conducted
within the Melbourne Collaborative Cohort Study (MCCS),
a prospective cohort study of 41 514 participants
(25% Southern European migrants) aged predominantly
between 40 and 69 years at study recruitment (1990–
1994). Details of the study design, recruitment and pro-
cedures are published elsewhere(14).
At baseline participants were interviewed about lifestyle
and medical history, completed a self-administered 121-item
FFQ developed for the MCCS(15), and anthropometric mea-
surements (height, weight, waist and hip circumferences)
were performed according to a standard protocol. Blood
samples were collected and from the second year of
recruitment (approximately 75% of participants), whole
blood was spotted on to Guthrie cards that were air dried
and stored in the dark at room temperature. About four
years after baseline, participants were mailed a ques-
tionnaire that included a question about their general health
status, rated as poor, fair, good, very good or excellent.
Case–cohort study
Eligibility for the case–cohort study was restricted to
29 206 participants who had dried blood spot samples and,
to reduce the possibility of reverse causality, no cancer
diagnosed before baseline. The present analysis was
restricted to the 2410 people who died by 31 December
2007 and the sub-cohort, a sex-stratiﬁed random sample of
2996 participants, with sampling fractions of 7·8% for
women and 13·6% for men, approximately double the
number of incident breast cancer and prostate cancer
cases, respectively (Fig. 1).
Measurement of 25-hydroxyvitamin D
The mean time between blood sampling and 25(OH)D
measurement was 18·1 (SD 0·8) years. Concentration of
25(OH)D3 has previously been shown to be stable in dried
blood spots stored for 8–22 years(16). Measurements of
25(OH)D2 and 25(OH)D3 were made in the laboratory of
D.W.E. using LC–MS/MS(16) over 15 months in thirty-one
batches of approximately 230 samples each. This labora-
tory uses National Institute of Standards and Technology
calibrants and participates in the Vitamin D External
Quality Assessment Scheme. The absolute limits of
detection were 1 nmol/l for 25(OH)D3 and 2 nmol/l for
25(OH)D2
(16). We have previously reported high reliability
of dried blood spot 25(OH)D measurements using 493
replicates from the case–cohort study; within- and
between-batch intraclass correlations were 0·82 (95% CI
0·80, 0·85) and 0·73 (95% CI 0·68, 0·78), respectively(17).
To estimate the reliability of the 25(OH)D2 measurements,
we calculated the intraclass correlation coefﬁcient for the
presence v. absence of 25(OH)D2 for the 493 replicate
measurements. For a binary variable with two replicates,
the intraclass correlation is the same as Cohen’s κ. We
calculated bias-corrected CI using a bootstrap method
with 10 000 replications. The intraclass correlation for
detectability of 25(OH)D2 was 0·54 (95% CI 0·25, 0·72).
Direct comparison between dried blood spot and
serum/plasma 25(OH)D concentrations is problematic
because 25(OH)D is excluded from erythrocytes.
Therefore, for initial descriptions of the concentrations, we
corrected the observed concentrations for mean sex-
speciﬁc haematocrit(17). For all other analyses of 25(OH)D
and 25(OH)D3, we used a calibration equation to
predict plasma concentration(17). In a subset of sixty-two
MCCS participants who had dried blood spot and match-
ing plasma samples (two replicates for each biospecimen
type), we found good agreement between dried
blood spot 25(OH)D and plasma 25(OH)D concentrations
(R2= 0·73) and developed an equation to estimate
plasma 25(OH)D concentration from the dried blood spot
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concentration(17). Because few participants in that study had
detectable 25(OH)D2, the calibration equation applies to
total 25(OH)D and 25(OH)D3 only. The sensitivity and
speciﬁcity of 25(OH)D2 detection in the dried blood spot
samples compared with the plasma samples was respec-
tively 100·0 (95% CI 29·0 100·0) % and 94·9 (95% CI 85·9,
98·9) % for the ﬁrst replicate, and 50·0 (95% CI 7·0, 93·0) %
and 100·0 (95% CI 93·8, 100·0) % for the second replicate.
Ascertainment of deaths
Deaths to 31 December 2007 were identiﬁed by linkage to
the Victorian Registry of Births, Deaths and Marriages and
the National Death Index at the Australian Institute of
Health and Welfare.
Statistical analysis
Association between 25-hydroxyergocalciferol and
25-hydroxycholecalciferol
One participant whose 25(OH)D2 concentration was several
times higher than the next highest value was excluded from
these analyses. For participants with detectable 25(OH)D2,
we estimated Spearman’s correlation between the raw
25(OH)D3 and 25(OH)D2 concentrations. We used linear
regression to estimate the difference in mean plasma
25(OH)D and 25(OH)D3 concentrations for participants with
and without detectable 25(OH)D2, with adjustment for sex.
For the regression analyses, we used estimated plasma
25(OH)D and 25(OH)D3 concentrations derived from our
calibration equation(17), but did not remove season and
batch effects. The adjustment for sex was necessary because
men had higher 25(OH)D and 25(OH)D3 concentrations
and were more likely to have detectable 25(OH)D2.
Association between vitamin D and mortality
Participants with missing data for covariates (n 44) and
those with extreme total energy intakes (<1st and >99th
sex-speciﬁc percentiles; n 100) were excluded (Fig. 1).
Total 25(OH)D and 25(OH)D3 concentrations were
adjusted for batch and season, then converted to plasma-
equivalent values using our calibration equation(17). To
remove batch effects, we ﬁrst ﬁtted a mixed-effects linear
regression model with a random effect for batch to the
sub-cohort observations. Next, for all observations, the
predicted batch-speciﬁc deviations from the overall mean
were subtracted from the observed values. Seasonal
variation was removed by ﬁtting linear regression models
for 25(OH)D and 25(OH)D3 as a sinusoidal function of the
time of year when blood was sampled(18), then standar-
dising measurements to represent 25(OH)D and 25(OH)D3
measurements on the dates when the annual mean was
attained (15 May and 14 November; late autumn and
late spring in Australia). Participants were grouped into
sex-speciﬁc quintiles based on the distribution of
batch- and season-adjusted 25(OH)D or 25(OH)D3 in
the sub-cohort. For 25(OH)D2, batch and seasonal
adjustments were not performed because there were too
few participants with detectable 25(OH)D2.
Cox regression was used to estimate hazard ratios (HR)
and 95% CI. Barlow’s method, robust SE(19) and Wald tests
were used to account for the case–cohort design. Age was
the timescale and models were stratiﬁed by sex and
country of birth. Follow-up began at baseline and ended at
the date of death, date left Australia or 31 December 2007,
whichever came ﬁrst. The proportional hazards assump-
tion was assessed by ﬁtting interactions between each
covariate separately and attained age. There was no
evidence that any covariate violated the assumptions.
We estimated HR for all-cause mortality for each quin-
tile of 25(OH)D and 25(OH)D3 relative to the lowest
quintile and for the presence v. absence of detectable
25(OH)D2, adjusting for confounders described below.
For 25(OH)D and 25(OH)D3 we also estimated the HR per
25nmol/l by using the continuous forms of the variables.
We ﬁtted models with each vitamin D variable alone, a
model including continuous 25(OH)D and its interaction
with detectable 25(OH)D2, and a model including main
effects for continuous 25(OH)D3 and detectable 25(OH)D2.
The interaction model assesses whether the relationship
between 25(OH)D and mortality depends on the source of
the 25(OH)D. Effect modiﬁcation by sex was assessed by
ﬁtting interactions between each vitamin D variable
(continuous for 25(OH)D and 25(OH)D3) and sex.
Confounders
The following confounders were selected using a causal
diagram and a priori knowledge from existing literature:
age, sex, country of birth (Australia/New Zealand/North-
ern Europe or Southern Europe), an area-based measure
of socio-economic disadvantage (quintiles from most dis-
advantaged to least disadvantaged), highest education
level attained (primary school, some secondary school,
secondary school, tertiary qualiﬁcation), total energy
intake (sex-speciﬁc quartiles, kJ/d), Mediterranean diet
score (three categories indicating dietary pattern, with the
highest representing high adherence to a Mediterranean
diet), alcohol (never, former and sex-speciﬁc tertiles of
current intake), smoking (never, former, current), physical
activity (four categories reﬂecting frequency and intensity
of exercise in the past 6 months), waist circumference
(sex-speciﬁc quartiles, centimetres), and self-reported
history of diabetes mellitus, hypertension and CVD
(angina, myocardial infarction or stroke).
Sensitivity analyses
We repeated the analyses for the continuous versions of
25(OH)D and 25(OH)D3 after excluding participants whose
values were greater than the 99th percentiles to assess
whether outliers had undue inﬂuence on the HR. We also
assessed non-linearity of the dose–response relationships by
ﬁtting restricted cubic spline models with four knots at ﬁxed,
equally spaced percentiles (5%, 35%, 65%, 95%).
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People in poor health may have had reduced sun expo-
sure, leading to lower 25(OH)D3. They may also have taken
supplements, leading to higher 25(OH)D2, since vitamin D
supplements in Australia in the early 1990s contained
ergocalciferol(20). Thus, observed associations between
vitamin D and mortality could potentially be explained by
reverse causality. To assess this possibility, a sensitivity
analysis was conducted by restricting the analysis to people
who reported having good, very good or excellent health on
the 4-year follow-up questionnaire. For that analysis, follow-
up began on the date of completion of that questionnaire.
Analyses were performed using the statistical software
package Stata version 13·1.
Results
Dried blood spots were not located for sixteen participants
and seven deaths were identiﬁed after the study began,
leaving 5108 for analysis (Fig. 1). All samples had detect-
able concentrations of 25(OH)D3 (range for haematocrit-
corrected values, 2·4–146·9 nmol/l; to convert 25(OH)D in
nmol/l to ng/ml, divide by 2·496), whereas 25(OH)D2 was
detected in sixty-three samples (1·2%; range for
haematocrit-corrected values, 4·1–195·0 nmol/l). The
median plasma-equivalent 25(OH)D concentration,
adjusted for batch and season, was 48·4 nmol/l; 99% of
values were greater than 19·7 nmol/l and 1% greater than
107·3 nmol/l.
Participants who were born in Southern Europe, had
primary school education or less, were in the lowest
energy intake quartile, did not consume alcohol (both
lifetime abstainers and former drinkers), were current
smokers, did not do any physical activity, were in the
largest waist circumference quartile or had diabetes
mellitus at baseline were more likely to have low 25(OH)D3
concentrations (Table 1). These patterns were almost
identical for 25(OH)D (data not shown). Participants with
high alcohol consumption and current smokers were less
likely to have 25(OH)D2, while those who took multi-
vitamins were more likely to have 25(OH)D2 (Table 2).
The mean plasma 25(OH)D concentration was 11·9
(95% CI 7·3, 16·6) nmol/l higher (P< 0·001) when
25(OH)D2 was detected than when it was not detected,
whereas the mean plasma 25(OH)D3 concentration was
4·9 (95% CI −9·6, −0·3) nmol/l lower (P= 0·04). For
participants with detectable 25(OH)D2 there was a weak,
non-signiﬁcant inverse correlation between their raw
25(OH)D2 and 25(OH)D3 concentrations (Spearman’s
correlation = −0·09, P= 0·50).
Vitamin D and mortality
During a mean of 13·7 (SD 2·2) years of follow-up (max-
imum 16·9 years), 2410 (8·3%) participants died. The
present analysis included 4964 participants, 2307 of whom
died (Fig. 1).
The HR for the highest compared with the lowest total
25(OH)D quintile was 0·67 (95% CI 0·54, 0·84) and the HR
per 25 nmol/l increment in 25(OH)D was 0·86 (95% CI
0·78, 0·96; P= 0·007; Table 3). There was no evidence that
the splines ﬁtted better than a linear trend (P= 0·44) and
the HR was unchanged after excluding outliers (data
not shown).
Because few participants had 25(OH)D2, the HR for
25(OH)D3 were essentially identical to those for total
25(OH)D (Table 3). The splines ﬁtted no better than a
linear trend (P= 0·42) and excluding outliers did not
affect the HR (data not shown). The HR for the presence of
detectable 25(OH)D2 was 1·80 (95% CI 1·09, 2·97;
P= 0·02; Table 3). One batch of measurements had a
disproportionate number of samples with 25(OH)D2;
results were similar when this batch was excluded
(HR= 1·88; 95% CI 1·07, 3·28; P= 0·03).
When 25(OH)D3 and detectable 25(OH)D2 were
included in the same model, their HR changed little
(Table 3). The interaction between the continuous
25(OH)D and 25(OH)D2 was signiﬁcant (P= 0·02). From
this model, the HR per 25 nmol/l increment in 25(OH)D
concentration was 0·85 (95% CI 0·77, 0·95) when there
was no detectable 25(OH)D2 and 1·06 (95% CI 0·87, 1·29)
when there was detectable 25(OH)D2.
There was little evidence that the HR for any of the
vitamin D variables varied by sex (interactions: 25(OH)D,
P= 0·30; 25(OH)D3, P= 0·28; 25(OH)D2, P= 0·25).
Vitamin D and mortality in people reporting good
health
When restricted to the 3159 participants (1136 of whom
died) who reported good, very good or excellent health
four years after baseline blood sample collection, forty-six
had detectable 25(OH)D2. The HR per 25 nmol/l incre-
ment in 25(OH)D and 25(OH)D3 were 0·85 (95% CI 0·73,
0·98; P= 0·021) and 0·83 (95% CI 0·72, 0·95; P= 0·009),
respectively. The HR for detectable 25(OH)D2 was 1·75
(95% CI 0·98, 3·10; P= 0·06). The HR from the model
including 25(OH)D and the interaction with detectable
25(OH)D2 were also similar to those for all participants
(data not shown).
Discussion
Higher 25(OH)D3 and 25(OH)D concentrations were
associated with a moderately reduced risk of death,
whereas the presence of 25(OH)D2 was associated with a
moderately increased risk of death, despite participants
with detectable 25(OH)D2 having higher mean 25(OH)D
concentration. The inverse association between mortality
and 25(OH)D was restricted to those with no detectable
25(OH)D2. The HR for 25(OH)D3 and detectable
25(OH)D2 changed little when they were included in
the same model. These associations were similar when the
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analysis was restricted to people who reported being in
good to excellent health about four years after blood draw.
Strengths of the current study include its prospective
design, long follow-up, use of highly sensitive LC–MS/MS
for separate measurement of both 25(OH)D forms,
availability of extensive information on potential con-
founders, accurate and complete mortality data, and broad
generalisability. Measurement error is unlikely to explain
the associations: the samples were analysed in random
order and blind to outcome status and so any measure-
ment error would be non-differential and attenuate
associations. We had no data on vitamin D supplementa-
tion, but only 16% of participants reported using multi-
vitamins at baseline (which at the time in Australia
contained ergocalciferol only, but which now contain
cholecalciferol only). We controlled for history of disease
Melbourne Collaborative Cohort Study
n 41 514
Eligible
n 29 206
Exclusions:
• Missing confounder data, 
   n 44
• Extreme total energy 
   intakes, n 100
Total
n 5131
(275 sub-cohort participants died)
Deaths
n 2307
Sub-cohort
n 2923
Exclusions:
• Vitamin D measurements 
   not performed, n 23
Pre-baseline cancer or no 
baseline dried blood spot 
sample
n 12 308
Deaths
n 2410
Sub-cohort
n 2996
Association between 25(OH)D2 and 25(OH)D3
n 5108
(273 sub-cohort participants died)
Mortality analysis
n 4964
(266 sub-cohort participants died)
Fig. 1 Flow of participants in the present study. The sub-cohort was a sex-stratified random sample of eligible participants.
Deaths were all deaths between baseline (1990–1994) and 31 December 2007 (25(OH)D2, 25-hydroxyergocalciferol; 25(OH)D3,
25-hydroxycholecalciferol)
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Table 1 Baseline characteristics of sub-cohort participants included in the mortality analyses (n 2923) according to quintiles of batch-
and season-adjusted plasma 25-hydroxycholecalciferol (25(OH)D3) concentrations (plasma concentration estimated from calibration
equation(17)); Melbourne Collaborative Cohort Study
25(OH)D3 quintile (nmol/l)*
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
(n 583; 20·0%) (n 585; 20·0%) (n 585; 20·0%) (n 585; 20·0%) (n 585; 20·0%)
Median
or n
IQR or
%
Median
or n
IQR or
%
Median
or n
IQR or
%
Median
or n
IQR or
%
Median
or n
IQR or
%
Plasma 25(OH)D3 (nmol/l), median and IQR
Overall 30·2 6·3 41·3 8·7 51·2 11·8 60·8 14·8 75·2 21·3
Females 29·1 4·9 36·5 3·4 42·9 3·4 50·6 4·5 62·7 10·3
Males 32·2 8·8 45·2 5·2 54·7 4·6 65·3 6·4 82·8 14·7
Male sex 322 20·0 323 20·0 323 20·0 323 20·0 323 20·0
Number of deaths
Females 17 21·3 24 30·0 11 13·8 12 15·0 16 20·0
Males 45 24·2 37 19·9 40 21·5 33 17·7 31 16·7
Age (years), median and IQR 53·8 15·3 54·3 14·8 53·2 14·8 53·6 15·3 54·1 15·9
Country of birth
Australia/NZ/Northern Europe 409 16·7 443 18·1 495 20·3 541 22·1 555 22·7
Southern Europe 174 36·3 142 29·6 90 18·8 44 9·2 30 6·3
Socio-economic disadvantage
1st quintile (most disadvantage) 81 21·2 69 18·0 76 19·8 84 21·9 73 19·1
2nd quintile 101 21·1 104 21·8 91 19·0 98 20·5 84 17·6
3rd quintile 87 18·0 97 20·1 101 20·9 98 20·3 100 20·7
4th quintile 135 20·0 131 19·4 135 20·0 141 20·9 134 19·8
5th quintile (least disadvantage) 179 19·8 184 20·4 182 20·2 164 18·2 194 21·5
Education
Primary school or less 95 28·7 102 30·8 55 16·6 45 13·6 34 10·3
Some secondary school 189 17·2 203 18·5 222 20·2 233 21·2 253 23·0
Secondary school 138 19·9 112 16·2 156 22·5 138 19·9 149 21·5
Tertiary 161 20·2 168 21·0 152 19·0 169 21·2 149 18·7
Energy intake (kJ/d, sex-specific quartiles)†
1 174 23·8 164 22·5 138 18·9 130 17·8 124 17·0
2 144 19·7 137 18·7 147 20·1 147 20·1 156 21·3
3 144 19·7 127 17·4 152 20·8 151 20·6 158 21·6
4 121 16·6 157 21·5 148 20·3 157 21·5 147 20·1
Mediterranean diet score
1 (low) 147 20·6 139 19·4 154 21·5 131 18·3 144 20·1
2 (medium) 370 20·2 355 19·4 358 19·6 380 20·8 367 20·1
3 (high) 66 17·5 91 24·1 73 19·3 74 19·6 74 19·6
Alcohol intake (g/d)‡
Never 152 23·2 140 21·3 131 20·0 119 18·1 114 17·4
Former 35 27·3 26 20·3 25 19·5 20 15·6 22 17·2
Low 127 18·5 142 20·7 141 20·5 128 18·6 149 21·7
Medium 135 19·3 118 16·9 148 21·2 151 21·6 147 21·0
High 134 17·8 159 21·1 140 18·6 167 22·2 153 20·3
Smoking status
Never 313 19·8 321 20·3 302 19·1 327 20·7 320 20·2
Former 190 18·7 196 19·3 214 21·0 200 19·7 217 21·3
Current 80 24·8 68 21·1 69 21·4 58 18·0 48 14·9
Physical activity score
None 158 26·5 133 22·3 110 18·5 103 17·3 92 15·4
Low 124 21·7 126 22·1 115 20·1 105 18·4 101 17·7
Medium 199 19·9 201 20·1 209 20·9 189 18·9 200 20·0
High 102 13·5 125 16·5 151 19·9 188 24·8 192 25·3
Waist circumference (cm, sex-specific quartiles)‡,§
1 127 17·7 147 20·5 126 17·6 149 20·8 169 23·5
2 124 16·9 135 18·4 153 20·9 157 21·4 164 22·4
3 142 19·1 151 20·4 168 22·6 153 20·6 128 17·3
4 190 26·0 152 20·8 138 18·9 126 17·3 124 17·0
History of diabetes mellitus 28 35·9 15 19·2 16 20·5 12 15·4 7 9·0
History of hypertension 101 19·0 113 21·2 107 20·1 93 17·5 118 22·2
History of CVD (angina, myocardial infarction or stroke) 35 19·0 43 23·4 35 19·0 27 14·7 44 23·9
IQR, interquartile range; NZ, New Zealand.
Values are median and interquartile range for 25(OH)D3 concentrations and age, or number and percentage for categorical variables.
*To convert 25(OH)D in nmol/l to ng/ml, divide by 2·496.
†Quartiles of total energy intake (kJ/d): 1, females= 3149–6301, males= 3755–7399; 2, females= 6302–8007, males= 7400–9192; 3, females= 8008–9827,
males=9193–11397; 4, females= 9828–18 831, males= 11398–22 150.
‡Categories of alcohol intake (g/d): low, females 0·1–4·2, males 0·1–9·2; medium, females 4·3–14·9, males 9·3–25·7; high, females 15·0–117·6, males 25·8–221·4.
§Quartiles of waist circumference (cm): 1, females=52·7–70·6, males=62·0–85·9; 2, females=70·7–76·9, males=86·0–91·9; 3, females=77·0–85·9, males=
92·0–98·4; 4, females=86·0–134·9, males=98·5–131·0.
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and several risk factors, but cannot rule out the possibility
of residual confounding. Given the small number of
people with detectable 25(OH)D2, chance is also a
potential explanation for its positive association with
mortality.
Inclusion of middle-aged adults with no pre-baseline
cancer reduced the possibility of reverse causality
explaining the results. However, reverse causality might
explain the positive association with 25(OH)D2 and
inverse association with 25(OH)D3 if people in poor
health were more likely to take supplements and
spend less time outdoors, thus having lower concentra-
tions of 25(OH)D3. Our sensitivity analysis, restricted to
participants in good to excellent health several years
after baseline, was designed to assess this possibility.
While it is not possible to rule out reverse causality,
the sensitivity analysis showed no evidence of its occur-
rence. The HR for total 25(OH)D and 25(OH)D3 were
very similar; this might not be the case in populations with
more ergocalciferol use, such as in the USA(2). Finally, the
absolute 25(OH)D values reported should be interpreted
cautiously as these were plasma-equivalent 25(OH)D
concentrations estimated from measurements of 25(OH)D
in dried blood spots and with adjustment for batch and
season.
A recent meta-analysis of cohort studies of vitamin D
and all-cause mortality found a relative risk (RR) of 1·16
(95% CI 1·08, 1·23) for a 10 ng/ml decrease in 25(OH)D,
which is equivalent to 0·86 (95% CI 0·81, 0·93) for a
25 nmol/l increase, and thus identical to the estimate from
our study for 25(OH)D(1). There was substantial hetero-
geneity between studies (I 2= 90%) that did not appear to
be explained by any of the study characteristics used to
form subgroups (no formal meta-regression was per-
formed). The association was similar when stratiﬁed by
latitude (≤40° v. >40°) and by age at baseline (<70 v. ≥70
years)(1). It was slightly stronger for males, whereas we
found similar associations for men and women. The
association was stronger in the ﬁrst ﬁve years after base-
line(1). One possible explanation for this ﬁnding is reverse
causality – our study is one of few that have been able to
assess this possibility by performing an analysis restricted
to people in good health several years after baseline. Our
results for 25(OH)D are also consistent with a recent meta-
analysis of individual data from eight cohort studies from
Europe and the USA, in which the RR for mortality in the
lowest v. the highest quintile was 1·57 (95% CI 1·36, 1·81),
which is equivalent to RR of 0·64 (= 1/1·57) for the highest
v. the lowest quintile (our corresponding HR was 0·67)(21).
In that study, there was also little heterogeneity by age and
sex(21). Some cohort studies have found U-shaped or
reverse J-shaped relationships between 25(OH)D and
all-cause mortality(22–25) but we found no such evidence.
However, because few of our participants had con-
centrations above 100 nmol/l, our ability to assess curvi-
linear relationships was limited.
Table 2 Presence of 25-hydroxyergocalciferol (25(OH)D2)
according to baseline characteristics of study participants;
Melbourne Collaborative Cohort Study
25(OH)D2 present
N n %
Participants 5108 63 1·2
Sex
Female 2255 22 1·0
Male 2853 41 1·4
Country of birth
Australia/NZ/Northern Europe 4260 56 1·3
Southern Europe 848 7 0·8
Socio-economic disadvantage
1st quintile (most disadvantage) 755 10 1·3
2nd quintile 940 15 1·6
3rd quintile 857 11 1·3
4th quintile 1111 13 1·2
5th quintile (least disadvantage) 1422 14 1·0
Education
Primary school or less 729 9 1·2
Some secondary school 1988 16 0·8
Secondary school 1190 23 1·9
Tertiary 1200 15 1·3
Alcohol intake (g/d)*
Never 1251 20 1·6
Former 245 2 0·8
Low 1169 16 1·4
Medium 1083 15 1·4
High 1352 10 0·7
Smoking status
Never 2520 36 1·4
Former 1877 23 1·2
Current 710 4 0·6
Physical activity score
None 1067 12 1·1
Low 964 10 1·0
Medium 1899 29 1·5
High 1177 12 1·0
Waist circumference (cm, sex-specific quartiles)†
1 1127 17 1·5
2 1149 19 1·7
3 1295 10 0·8
4 1525 17 1·1
Multivitamin use
No 4297 33 0·8
Yes 811 30 3·7
Mushroom consumption (frequency, categorized)
Never or less than once per month 1565 24 1·5
Monthly 1624 17 1·1
Weekly 1919 22 1·2
Margarine intake (times/week, quartiles)
0–0·4 1101 14 1·3
0·5–6·9 1363 17 1·3
7·0–17·4 1186 19 1·6
≥17·5 1450 13 0·9
History of hypertension
No 3860 44 1·1
Yes 1246 18 1·4
History of CVD (angina, myocardial infarction
or stroke)
No 4563 56 1·2
Yes 544 7 1·3
NZ, New Zealand.
All values are number and percentage.
*Categories of alcohol intake (g/d): low, females= 0·1–4·2, males= 0·1–9·2;
medium, females= 4·3–14·9, males= 9·3–25·7; high, females= 15·0–157·9,
males= 25·8–232·2.
†Quartiles of waist circumference (cm): 1, females= 47·0–70·5,
males= 62·0–85·9; 2, females= 70·6–76·9, males= 86·0–91·9; 3, females=
77·0–85·4, males= 92·0–98·3; 4, females= 85·5–153·6, males=
98·4–143·0.
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We are not aware of any cohort studies of 25(OH)D2
and 25(OH)D3 and mortality. According to a Cochrane
review of RCT of vitamin D supplementation, cholecalci-
ferol reduced all-cause mortality by 6% (RR= 0·94; 95% CI
0·91, 0·98; P= 0·002). Ergocalciferol had no apparent
beneﬁcial effect (RR= 1·02; 95% CI 0·96, 1·08; P= 0·54),
but in RCT involving participants with vitamin D insufﬁ-
ciency, the risk of mortality was elevated (RR= 1·20; 95%
CI 1·05, 1·37; P= 0·008)(5). The authors commented that
‘the effect of vitamin D2 may be neutral or even detri-
mental’(5). In another meta-analysis of RCT, cholecalciferol
supplementation reduced all-cause mortality (RR= 0·89;
95% CI 0·80, 0·99). Overall, ergocalciferol had no bene-
ﬁcial effect (RR= 1·04; 95% CI 0·97, 1·11), but increased
mortality risk in RCT using doses of 15–50 µg/d (600–
2000 IU/d; RR= 1·20; 95% CI 1·05, 1·38), in RCT with
shorter mean intervention periods (<1·5 years; RR= 1·20;
95% CI 1·05, 1·37) and in RCT with shorter follow-up
(<2·5 years; RR= 1·19; 95% CI 1·04, 1·36)(1). The median
follow-up from the included RCT was only 1·4 years, the
median age of participants was 77 years, there were
relatively few deaths in each study, and thirteen out of the
twenty-two RCT involved participants with pre-existing
chronic disease(1). Thus, existing RCT are not necessarily
generalisable to younger/middle-aged community-dwelling
populations.
Our ﬁndings that participants with detectable 25(OH)D2
had higher mean 25(OH)D but lower mean 25(OH)D3
concentration is consistent with the Osteoporotic Fractures
in Men Study (MrOS)(26). These ﬁndings complement
evidence from RCT showing that ergocalciferol might
interfere with production of 25(OH)D3 and/or induce
processes that degrade 25(OH)D3
(7–13).
Several potential mechanisms could explain differences
in effects of ergocalciferol and cholecalciferol. The pre-
sence of a methyl group on C24 of ergocalciferol meta-
bolites may slightly alter their ability to bind to, or their
afﬁnity for, vitamin D binding protein(27), vitamin D
hydroxylases and the vitamin D receptor(28). The lower
afﬁnity of 25(OH)D2 for vitamin D binding protein relative
to 25(OH)D3 means its free fraction in blood is likely to be
higher, consistent with the faster turnover of 25(OH)
D2
(8,27). The shorter circulating half-life of ergocalciferol
metabolites may lead to up-regulation of enzymes
that not only metabolise ergocalciferol, but also con-
comitantly induce accelerated catabolism and clearance
of 25(OH)D3
(8,11).
Differential speciﬁcities of the various cytochrome
P450 (CYP) enzymes that metabolise vitamin D may also
help to explain the apparent effect of ergocalciferol
on 25(OH)D3 concentration. While the microsomal
vitamin D 25-hydroxylase, CYP2R1, 25-hydroxylates both
Table 3 Hazard ratios (HR) and 95% CI for all-cause mortality for total 25-hydroxyvitamin D (25(OH)D), 25-hydroxycholecalciferol
(25(OH)D3) and 25-hydroxyergocalciferol (25(OH)D2); Melbourne Collaborative Cohort Study
Concentration (nmol/l)* Single-variable model Two-variable model
Median IQR n Deaths Person-years† HR‡ 95% CI Ptrend HR‡ 95% CI Ptrend
Total plasma 25(OH)D§
Quintile
Q1 30·3 7·6 1067 545 7885 1·00 ref. 0·001
Q2 41·3 8·9 1008 485 7977 0·85 0·68, 1·06
Q3 51·6 11·8 992 458 8020 0·90 0·72, 1·11
Q4 61·0 14·9 958 417 8056 0·80 0·64, 1·00
Q5 77·0 21·1 939 402 8150 0·67 0·54, 0·84
Per 25 nmol/l increase 4964 2307 40088 0·86 0·78, 0·96 0·007
25(OH)D2 absent 0·85|| 0·77, 0·95 0·003
25(OH)D2 present 1·06|| 0·87, 1·29 0·55
Plasma 25(OH)D3‡
Quintile
Q1 30·1 7·3 1066 545 7884 1·00 ref. 0·001
Q2 41·0 8·7 1011 487 7988 0·86 0·69, 1·08
Q3 51·4 11·6 991 457 8003 0·88 0·71, 1·10
Q4 60·7 14·3 953 413 8050 0·77 0·62, 0·97
Q5 76·2 20·9 943 405 8163 0·68 0·54, 0·85
Per 25 nmol/l increase 4964 2307 40088 0·85 0·77, 0·95 0·003 0·86¶ 0·77, 0·95 0·004
Plasma 25(OH)D2
Absent 0·0 0·0 4902 2273 39653 1·00 ref.
Present 13·7 9·2 62 34 436 1·80 1·09, 2·97 0·023 1·73¶ 1·05, 2·87 0·032
IQR, interquartile range; ref., reference category.
*To convert 25(OH)D in nmol/l to ng/ml, divide by 2·496.
†Sub-cohort participants.
‡Adjusted for age, area-based index of socio-economic disadvantage, education, total energy intake, Mediterranean diet pattern, alcohol intake, smoking
status, physical activity, waist measurement, diabetes mellitus at baseline, history of hypertension, history of angina, history of myocardial infarction, history of
stroke, and stratified by sex and Southern European migrant status.
§Adjusted for batch and seasonal effects.
||Interaction between 25(OH)D and 25(OH)D2.
¶Mutual adjustment for 25(OH)D2 and 25(OH)D3.
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ergocalciferol and cholecalciferol equally well(29,30),
mitochondrial CYP27A1 25-hydroxylates cholecalciferol(31),
but not ergocalciferol(32).
Another enzyme, CYP3A4, 25-hydroxylates ergocalci-
ferol and not cholecalciferol, but also 24-hydroxylates
several vitamin D metabolites(33–35). In particular, CYP3A4
plays a major role in 23- and 24-hydroxylation of the
biologically active form of cholecalciferol, 1,25-dihydroxy-
cholecalciferol (1,25(OH)2D3), in the liver and small
intestine(35). CYP3A4 is the most abundant liver cyto-
chrome P450 enzyme and has broad speciﬁcity,
catabolising more than 50% of known drugs(34,36). Many
drugs inhibit or induce CYP3A4, thereby potentially
increasing vitamin D turnover(33,35). It is possible that
ergocalciferol similarly induces CYP3A4, leading to
enhanced 23- and 24-hydroxylation of 1,25(OH)2D3;
inactivating cholecalciferol and ultimately eliminating it
from the body. Thus, a plausible explanation for the
inverse association between circulating 25(OH)D2 and
25(OH)D3, and any potential detrimental effect of
ergocalciferol on health, is enhanced CYP3A4-induced cat-
abolism of 1,25(OH)2D3 in the presence of ergocalciferol.
In summary, our results conﬁrm those of previous stu-
dies that higher levels of 25(OH)D are associated with
reduced mortality. For our study at least, this was due to
the inverse association between 25(OH)D3 and mortality.
Our ﬁndings with respect to 25(OH)D2 require conﬁrma-
tion in other populations with higher exposure to this form
of vitamin D.
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